ArticleCancer cell international2026
New proteomic signature in circulating extracellular vesicles from tumor-draining and peripheral veins of patients with lung adenocarcinoma.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04939324 (Analyse du Profil moléculaire Des Exosomes de la Veine Pulmonaire Dans le Cancer Bronchique de Stade précoce), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Analyse du Profil moléculaire Des Exosomes de la Veine Pulmonaire Dans le Cancer Bronchique de Stade précoce
Who cites it
2 citing papers in PubMed.
- Lung tumour secretome and extracellular vesicles: mechanisms, biomarkers, and therapeutic opportunities.Cancer metastasis reviews · 2026Review
- Extracellular Vesicles in Cancer: Biomarkers, Mechanisms, and Emerging Diagnostic Technologies.Advanced healthcare materials · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe identification of noninvasive prognostic biomarkers for monitoring relapse in patients with locally advanced lung cancer remains a primary objective. Tumor-draining vein (TDV) plasma samples are known to be enriched in cancer biomarkers compared to peripheral vein (PV) samples and may therefore facilitate biomarker discovery. In this exploratory study, we investigated both proteomic profile from tumor and non-tumor tissues and from extracellular vesicles (EVs) purified from TDV and PV plasma samples of patients undergoing surgery for lung adenocarcinoma.
methodsTwenty patients operated for a lung adenocarcinoma were enrolled. EVs purified from TDV and PV plasma samples were characterized for size distribution and concentration using nanoparticles tracking analysis. Proteomic profiling of both tissue and EVs was performed using mass spectrometry (nanoLC-MS/MS) analysis. Differential expression protein analysis in lung tissues from tumor compared to non-tumor counterpart and in EVs from TDV compared to EVs from PV were performed using DEP R package. Functional enrichment analysis and protein networking were conducted to gain biological insights into the set of deregulated proteins.
resultsTDV-derived EVs were significantly smaller and more concentrated than PV-derived EVs. Proteomic analysis revealed that 466 proteins were deregulated in tumor as compared to normal lung tissue, while 369 proteins were differentially detected in TDV- versus PV-derived EVs. Nine of the 10 most upregulated proteins in TDV-derived EVs compared to PV-derived EVs were previously associated to lung cancer diagnosis and prognosis. Notably, SRPRB (Signal recognition particle receptor subunit beta) was the only protein upregulated in both tumor tissues and TDV-derived EVs.
conclusionsThis exploratory study showed that this subset of proteins carried by EVs from TDV plasma, may represent candidate circulating biomarkers for early-stage lung adenocarcinoma prognosis.
trial registrationThe ExOnSite-Pro (Molecular Profiling of Exosomes in Tumor-draining Vein of Early-staged Lung Cancer, Clinical Trial Register number: NCT04939324, https://clinicaltrials.gov/study/NCT04939324 ) is a prospective trial conducted from June 2021 to June 2024. Ethical approval was granted on May 21, 2021 by the independent protection committee SUD MEDITERRANEE III (approval number 2021.05.02 bis_21.03.15.45551, FRANCE). Written informed consent was obtained from all participants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.